Evidence map›Paper›PMID 24192154›Full record

ArticleBMC pulmonary medicine2013

Nitric oxide synthase polymorphisms, gene expression and lung function in chronic obstructive pulmonary disease.

Farzian Aminuddin, Tillie-Louise Hackett, Dorota Stefanowicz, Aabida Saferali, Peter D Paré, Amund Gulsvik, Per Bakke, Michael H Cho, Augusto Litonjua, David A Lomas and 4 more

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 4 countries.

Farzian Aminuddin
Tillie-Louise Hackett
Dorota Stefanowicz
Aabida Saferali
Peter D Paré
Amund Gulsvik
Per Bakke
Michael H Cho
Augusto Litonjua
David A Lomas
Wayne H Anderson
Terri H Beaty
Edwin K Silverman
Andrew J SandfordThe University of British Columbia James Hogg Research Centre, Providence Heart + Lung Institute, Vancouver, Canada. andrew.sandford@hli.ubc.ca.
University of British Columbia · CABrigham and Women's Hospital · USHarvard University · USHaukeland University Hospital · NOJohns Hopkins University · USResearch Triangle Park Foundation · USUniversity of Bergen · NOUniversity of Cambridge · GB

Funding

REMODELING OF HUMAN AIRWAYS IN DISEASER01HL064068 · NHLBI · UNIVERSITY OF BRITISH COLUMBIA · PI PARE, PETER DAVID · 1999 to 2002
$600k
CIHRMedical Research Council G0901786NHLBI NIH HHS 5R01HL064068-04
6 · The paper itself

Abstract

backgroundDue to the pleiotropic effects of nitric oxide (NO) within the lungs, it is likely that NO is a significant factor in the pathogenesis of chronic obstructive pulmonary disease (COPD). The aim of this study was to test for association between single nucleotide polymorphisms (SNPs) in three NO synthase (NOS) genes and lung function, as well as to examine gene expression and protein levels in relation to the genetic variation.

methodsOne SNP in each NOS gene (neuronal NOS (NOS1), inducible NOS (NOS2), and endothelial NOS (NOS3)) was genotyped in the Lung Health Study (LHS) and correlated with lung function. One SNP (rs1800779) was also analyzed for association with COPD and lung function in four COPD case-control populations. Lung tissue expression of NOS3 mRNA and protein was tested in individuals of known genotype for rs1800779. Immunohistochemistry of lung tissue was used to localize NOS3 expression.

resultsFor the NOS3 rs1800779 SNP, the baseline forced expiratory volume in one second in the LHS was significantly higher in the combined AG + GG genotypic groups compared with the AA genotypic group. Gene expression and protein levels in lung tissue were significantly lower in subjects with the AG + GG genotypes than in AA subjects. NOS3 protein was expressed in the airway epithelium and subjects with the AA genotype demonstrated higher NOS3 expression compared with AG and GG individuals. However, we were not able to replicate the associations with COPD or lung function in the other COPD study groups.

conclusionsVariants in the NOS genes were not associated with lung function or COPD status. However, the G allele of rs1800779 resulted in a decrease of NOS3 gene expression and protein levels and this has implications for the numerous disease states that have been associated with this polymorphism.

Indexed as

Gene ExpressionPolymorphism, Single NucleotideAdultAgedCase-Control StudiesFemaleForced Expiratory VolumeGenotypeHumansMaleMiddle AgedNitric Oxide SynthaseNitric Oxide Synthase Type INitric Oxide Synthase Type IINitric Oxide Synthase Type IIIPulmonary Disease, Chronic ObstructiveNitric Oxide SynthaseNitric Oxide Synthase Type INitric Oxide Synthase Type IINitric Oxide Synthase Type IIIRNA, Messenger

Identifiers

PMID24192154
PMCPMC3827989
OpenAlexW2118594175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.